[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Sholomskas DE, Syracuse-Siewert G, Rounsaville BJ, Ball SA, Nuro KF, Carroll KM: We don't train in vain: a dissemination trial of three strategies of training clinicians in cognitive-behavioral therapy. J Consult Clin Psychol; 2005 Feb;73(1):106-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] We don't train in vain: a dissemination trial of three strategies of training clinicians in cognitive-behavioral therapy.
  • There has been little research on the effectiveness of different training strategies or the impact of exposure to treatment manuals alone on clinicians' ability to effectively implement empirically supported therapies.
  • Seventy-eight community-based clinicians were assigned to 1 of 3 training conditions: review of a cognitive-behavioral therapy (CBT) manual only, review of the manual plus access to a CBT training Web site, or review of the manual plus a didactic seminar followed by supervised casework.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 APA.
  • [Cites] JAMA. 1999 Oct 13;282(14):1314-6 [10527162.001]
  • [Cites] JAMA. 1999 Sep 1;282(9):861-6 [10478693.001]
  • [Cites] J Consult Clin Psychol. 1999 Aug;67(4):563-70 [10450627.001]
  • [Cites] Arch Gen Psychiatry. 1999 Jun;56(6):493-502 [10359461.001]
  • [Cites] J Consult Clin Psychol. 1998 Jun;66(3):484-92 [9642886.001]
  • [Cites] J Consult Clin Psychol. 1998 Apr;66(2):290-303 [9583332.001]
  • [Cites] Ann Emerg Med. 1998 Mar;31(3):364-9 [9506495.001]
  • [Cites] J Consult Clin Psychol. 1997 Oct;65(5):821-33 [9337501.001]
  • [Cites] Psychol Bull. 1997 Sep;122(2):170-91 [9283299.001]
  • [Cites] J Gen Intern Med. 1997 May;12(5):274-83 [9159696.001]
  • [Cites] J Consult Clin Psychol. 1995 Feb;63(1):70-8 [7896993.001]
  • [Cites] Arch Gen Psychiatry. 1994 Mar;51(3):177-87 [8122955.001]
  • [Cites] J Consult Clin Psychol. 1993 Aug;61(4):620-30 [8370857.001]
  • [Cites] Compr Psychiatry. 1986 Jul-Aug;27(4):364-71 [3524986.001]
  • [Cites] J Consult Clin Psychol. 1982 Oct;50(5):744-56 [7142549.001]
  • [Cites] Am J Psychiatry. 1982 Nov;139(11):1442-6 [7137394.001]
  • [Cites] Arch Gen Psychiatry. 2004 Mar;61(3):264-72 [14993114.001]
  • [Cites] J Subst Abuse Treat. 2002 Dec;23(4):309-18 [12495792.001]
  • [Cites] Med Educ. 2002 Feb;36(2):125-34 [11869439.001]
  • [Cites] Addiction. 2001 Dec;96(12):1725-42 [11784466.001]
  • [Cites] J Consult Clin Psychol. 2001 Dec;69(6):1007-17 [11777104.001]
  • [Cites] Behav Res Methods Instrum Comput. 2001 May;33(2):277-81 [11447684.001]
  • [Cites] Psychol Addict Behav. 2001 Jun;15(2):83-8 [11419234.001]
  • [Cites] Drug Alcohol Depend. 2000 Jan 1;57(3):225-38 [10661673.001]
  • [Cites] Drug Alcohol Depend. 2000 Feb 1;58(1-2):55-66 [10669055.001]
  • [Cites] Addiction. 2010 Oct;105(10):1799-808 [20840200.001]
  • [Cites] Psychol Bull. 1979 Mar;86(2):420-8 [18839484.001]
  • (PMID = 15709837.001).
  • [ISSN] 0022-006X
  • [Journal-full-title] Journal of consulting and clinical psychology
  • [ISO-abbreviation] J Consult Clin Psychol
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R44 AA014456-02; United States / NIDA NIH HHS / DA / K05 DA000457-02; United States / NIDA NIH HHS / DA / P50 DA009241-12; United States / NIDA NIH HHS / DA / DA015969-03; United States / NIDA NIH HHS / DA / R37 DA015969-04; United States / NIDA NIH HHS / DA / DA009241-11; United States / NIDA NIH HHS / DA / DA011352-01; United States / NIDA NIH HHS / DA / R44 DA 11352; United States / NIDA NIH HHS / DA / K05 DA000089-21; United States / NIDA NIH HHS / DA / DA000089-22; United States / NIDA NIH HHS / DA / R44 DA011352-03; United States / NIDA NIH HHS / DA / K05-DA00457; United States / NIAAA NIH HHS / AA / AA014456-02; United States / NIDA NIH HHS / DA / DA011352-03; United States / NIDA NIH HHS / DA / K05 DA000457-05; United States / NIDA NIH HHS / DA / DA000089-21; United States / NIDA NIH HHS / DA / P50 DA009241; United States / NIDA NIH HHS / DA / K05 DA000089-22; United States / NIDA NIH HHS / DA / R43 DA011352-01; United States / NIDA NIH HHS / DA / DA000089-20; United States / NIDA NIH HHS / DA / DA009241-12; United States / NIDA NIH HHS / DA / P50 DA009241-10; United States / NIDA NIH HHS / DA / K05 DA000457; United States / NIDA NIH HHS / DA / R01 DA015969; United States / NIDA NIH HHS / DA / R37 DA015969-02; United States / NIDA NIH HHS / DA / DA011352-02; United States / NIDA NIH HHS / DA / DA015969-01; United States / NIDA NIH HHS / DA / K05 DA000457-06; United States / NIDA NIH HHS / DA / P50 DA009241-11; United States / NIDA NIH HHS / DA / R37 DA015969-03; United States / NIDA NIH HHS / DA / DA000457-02; United States / NIDA NIH HHS / DA / DA015969-04; United States / NIDA NIH HHS / DA / K05 DA000457-04; United States / NIDA NIH HHS / DA / K05 DA00089; United States / NIDA NIH HHS / DA / DA015969-02; United States / NIDA NIH HHS / DA / P50 DA09241; United States / NIDA NIH HHS / DA / R01 DA015969-01; United States / NIDA NIH HHS / DA / K05 DA000089; United States / NIDA NIH HHS / DA / DA000457-06; United States / NIDA NIH HHS / DA / DA009241-10; United States / NIDA NIH HHS / DA / DA000457-05; United States / NIDA NIH HHS / DA / DA000457-04; United States / NIDA NIH HHS / DA / K05 DA000089-20; United States / NIDA NIH HHS / DA / R44 DA011352-02; United States / NIDA NIH HHS / DA / DA000457-03; United States / NIDA NIH HHS / DA / K05 DA000457-03; United States / NIDA NIH HHS / DA / R37 DA015969
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS46425; NLM/ PMC2367057
  •  go-up   go-down


2. Liou LM, Shih PY: Successful treatment of rubral tremor by high-dose trihexyphenidyl: a case report. Kaohsiung J Med Sci; 2006 Mar;22(3):149-53
Hazardous Substances Data Bank. TRIHEXYPHENIDYL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of rubral tremor by high-dose trihexyphenidyl: a case report.
  • Rubral tremor is not unusual, and pharmacotherapy is nearly always ineffective in clinical practice.
  • In our patient, we tried valproate, clonazepam, and verapamil one after another, but all in vain.
  • [MeSH-major] Ataxia / drug therapy. Trihexyphenidyl / therapeutic use

  • Genetic Alliance. consumer health - Tremor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16602280.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 6RC5V8B7PO / Trihexyphenidyl
  •  go-up   go-down


3. Hoshimoto S, Morise Z, Takeura C, Ikeda M, Kagawa T, Tanahashi Y, Okabe Y, Mizoguchi Y, Sugioka A: Malignant Triton tumor in the retroperitoneal space associated with neurofibromatosis type 1: a case study. Rare Tumors; 2009;1(2):e27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant Triton tumor in the retroperitoneal space associated with neurofibromatosis type 1: a case study.
  • We report an extremely rare case of malignant Triton tumor developing in the retroperitoneal space in a patient with neurofibromatosis type 1.
  • A 21-year old man who had been diagnosed with neurofibromatosis type 1 was admitted to our hospital with the chief complaint of a palpable abdominal mass.
  • Abdominal computed tomography revealed a huge heterogeneous tumor measuring approximately 17 cm in diameter occupying the left retroperitoneal space, and numerous metastatic lesions between the left psoas muscle and the left thigh with dissolution of the left hip joint.
  • After the diagnosis of a retroperitoneal malignant neurogenic tumor, resection of the tumor with reconstruction of the abdominal aorta was conducted, followed by postoperative transarterial infusion chemotherapy.
  • The histopathological diagnosis was malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation, namely malignant Triton tumor.
  • Postoperative chemotherapy was in vain and the patient died 14 months after the surgery as a result of lung metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139906.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994481
  • [Keywords] NOTNLM ; malignant Triton tumor / malignant peripheral nerve sheath tumor / neurofibromatosis / retroperitoneal tumor.
  •  go-up   go-down


Advertisement
4. Donato H, Bacciedoni V, García C, Schvartzman G, Vain N: [Recombinant erythropoietin as treatment for hyporegenerative anemia following hemolytic disease of the newborn]. Arch Argent Pediatr; 2009 Apr;107(2):119-25
MedlinePlus Health Information. consumer health - Rh Incompatibility.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recombinant erythropoietin as treatment for hyporegenerative anemia following hemolytic disease of the newborn].
  • [Transliterated title] Tratamiento de la anemia hiporregenerativa tardía de la enfermedad hemolítica del recién nacido con eritropoyetina recombinante.
  • INTRODUCTION: The aim of the study is to report results of erythropoietin treatment for late hyporegenerative anemia in the hemolytic disease of the newborn (HDN).
  • Erythropoietin treatment started when hematocrit dropped to levels requiring transfusion, with an inappropriate reticulocyte response (Reticulocyte Production Index <1).
  • RESULTS: At start of treatment mean age was 24.3 +/- 12.0 days (range 8-65 days), hematocrit 24.1 +/- 2.8% (range 18-30%), and Reticulocyte Production Index 0.34 +/- 0.25 (range 0.05-0.98).
  • Hematocrit and Reticulocyte Production Index showed significant increases after 7 and 14 days of treatment (p <0.001).
  • Seven infants (14%) required one packed RBC transfusion during erythropoietin therapy, 2 of them within 72 hours from starting treatment.
  • Moderate, short-lasting neutropenia, not associated to infections, was observed in 11 patients.
  • CONCLUSIONS: The administration of erythropoietin appears to be a safe and useful therapy.
  • [MeSH-major] Anemia, Aplastic / drug therapy. Anemia, Aplastic / etiology. Erythroblastosis, Fetal. Erythropoietin / therapeutic use

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452083.001).
  • [ISSN] 1668-3501
  • [Journal-full-title] Archivos argentinos de pediatría
  • [ISO-abbreviation] Arch Argent Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin
  •  go-up   go-down


5. Indraccolo U, Del Frate E, Cenci S, Ubertosi M, Donati Sarti R, Donati Sarti C, Baldoni A: [Vaginal intraepithelial neoplasia and human papillomavirus infection: a report of 75 cases]. Minerva Ginecol; 2006 Apr;58(2):101-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vaginal intraepithelial neoplasia and human papillomavirus infection: a report of 75 cases].
  • [Transliterated title] La neoplasia intraepiteliale vaginale e l'infezione da virus del papilloma umano. Un resoconto di 75 casi.
  • AIM: Vaginal intraepithelial neoplasia (VaIN) is an uncommon and poorly understood disease.
  • Risk factors other than human papillomavirus (HPV) infection could be linked to the onset and evolution of some VaIN.
  • METHODS: In this paper, the results achieved from the analysis of 75 patients with VaIN are reported.
  • From these cases, women with HIV, previous hysterectomy, autoimmune diseases and radio- and chemotherapy have been excluded.
  • They have been examined after a distinction between grade and association with coilocytosis.
  • VaIN preferential localization, mean age of patients and manifestation pattern after vaginal colposcopy have then been examined.
  • RESULTS: Although the population size cannot allow evidences, it seems that VaIN with coilocytosis and VaIN I without coilocytosis have preferential localization in the upper third of the vagina.
  • It does not appear that mean age of patients for each grade of VaIN differs significativly, both associated and not associated with coilocytosis.
  • Finally, after vaginal colposcopy, the pattern of VaIN for each grade is absolutely not typical, and it seems that white thin epithelium or negative Lugol area are usually the manifestation of high grades of VaIN too.
  • CONCLUSIONS: These results, if confirmed, could mean that VaIN due to HPV may have a different natural history relating to the site of localization in the vagina and, moreover, that also VaIN of high grade could appear with an innocent vaginal pattern.
  • [MeSH-major] Carcinoma in Situ / complications. Carcinoma in Situ / pathology. Papillomaviridae. Papillomavirus Infections / complications. Papillomavirus Infections / pathology. Vaginal Neoplasms / complications. Vaginal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16582866.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Haidopoulos D, Diakomanolis E, Rodolakis A, Voulgaris Z, Vlachos G, Intsaklis A: Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina? Int J Gynecol Cancer; 2005 Sep-Oct;15(5):898-902
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina?
  • The aim of the present study was to assess the local application of imiquimod cream 5% as an alternative mode of therapy for high-grade vaginal intraepithelial neoplasia (VAIN 2/3).
  • Positive human papillomavirus (HPV) patients with multifocal high-grade VAIN (2/3) not involving the vaginal vault in hysterectomized patients took part in this study.
  • The treatment consisted of vaginal application of the cream under colposcopic guidance.
  • Following management, biopsies were obtained from the previously recorded lesions. p53 expression was recorded prior and after therapy.
  • Seven patients with VAIN 2/3 took part in this study.
  • Six patients (86%) were positive for high-risk HPV type while three (43%) women who were positive for p53 nuclei prior to therapy were found to be negative following treatment.
  • After treatment, 86% of the patients were found to have either HPV infection or low-grade VAIN.
  • During follow-up, two patients (28.5%) were managed by vaginectomy, one for persistent and one for recurrent high-grade VAIN.
  • Currently, from the five patients that are followed, three have simple HPV infection and two, VAIN 1.
  • Imiquimod cream 5% might represent an alternative although not permanent method of management in young, HPV-positive women with multifocal high-grade lesions of the vagina (VAIN 2/3).
  • [MeSH-major] Aminoquinolines / administration & dosage. Aminoquinolines / therapeutic use. Epithelial Cells / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Middle Aged. Vaginal Creams, Foams, and Jellies / administration & dosage. Vaginal Creams, Foams, and Jellies / therapeutic use

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174242.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Vaginal Creams, Foams, and Jellies; 99011-02-6 / imiquimod
  •  go-up   go-down


7. Bergh J: Adjuvant chemotherapy for breast cancer--"one fits all"? Breast; 2005 Dec;14(6):564-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for breast cancer--"one fits all"?
  • Adjuvant breast cancer therapy and early diagnosis will improve breast cancer outcome.
  • So far, the very important survival gains by adjuvant therapy have been obtained by "one fits all"--like strategies, resulting in therapy in vain for many patients and unnecessary therapy for large cohorts.
  • Present adjuvant strategies have focused on group statistical risk analysis, mainly using tumour stage, histological grade and receptor status.
  • Five retrospective studies have revealed a worse outcome for patients receiving adjuvant chemotherapy without toxicity.
  • In one of these studies the breast cancer survival was improved by 10% for patients who received grade 2/3 neutropenia; this is equivalent to the described survival gains by the addition of anthracyclines and taxanes to cyclophosphamide, methotrexate, 5-fluorouracil (CMF) combinations.
  • Prospectively, this has been explored in the Scandinavian Breast Group (SBG) 9401-, SBG 2000-1- and presently in the SBG 2004-1 studies using tailored chemotherapy dosage strategies, aimed at avoiding under-dosage and diminishing acute side effects.
  • For the future, we need several predictive factors for therapy, allowing better and more tailored therapy selections for individuals at risk.
  • The present explorations of tumour RNA expression profiles are most likely to be useful in identifying therapy-predictive profiles for these individuals.
  • Pharmacokinetic and pharmacodynamic data reveal marked differences in effect and tolerance of used drugs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Europe. Female. Humans. Patient-Centered Care. Randomized Controlled Trials as Topic. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243525.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Scotland
  • [Number-of-references] 46
  •  go-up   go-down


8. Andersson S, Björholt I, Nilsson GH, Krakau I: Resource consumption and management associated with monitoring of warfarin treatment in primary health care in Sweden. BMC Fam Pract; 2006;7:67
Hazardous Substances Data Bank. WARFARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resource consumption and management associated with monitoring of warfarin treatment in primary health care in Sweden.
  • BACKGROUND: Warfarin is used for the prevention and treatment of various thromboembolic complications.
  • It is an efficacious anticoagulant, but it has a narrow therapeutic range, and regular monitoring is required to ensure therapeutic efficacy and at the same time avoid life-threatening adverse events.
  • The objective was to assess management and resource consumption associated with patient monitoring episodes during warfarin treatment in primary health care in Sweden.
  • METHODS: Delphi technique was used to systematically explore attitudes, demands and priorities, and to collect informed judgements related to monitoring of warfarin treatment.
  • Average time for one monitoring episode was estimated to 10.1 minutes for a GP and 21.4 minutes for a nurse, when a nurse assisted a doctor.
  • The average time for monitoring was 17.6 minutes for a GP when not assisted by a nurse.
  • Average time for such a monitoring episode was estimated to 88.2 minutes.
  • Of all the visits, 8.2% were performed in vain and took on average 44.6 minutes.
  • In both studies, approximately 20 different elements of work concerning management of patients during warfarin treatment were identified.
  • CONCLUSION: Monitoring of patients during treatment with warfarin in primary health care in Sweden involves many elements of work, and demands large resources, especially when tests are taken in the patient's home.
  • [MeSH-major] Anticoagulants / administration & dosage. Drug Monitoring / utilization. Family Practice / methods. Primary Health Care / methods. Thromboembolism / drug therapy. Time and Motion Studies. Warfarin / administration & dosage

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Adv Nurs. 2000 Oct;32(4):1008-15 [11095242.001]
  • [Cites] Cardiol Rev. 2001 Nov-Dec;9(6):325-8 [11696261.001]
  • [Cites] J Adv Nurs. 2003 Feb;41(4):376-82 [12581103.001]
  • [Cites] N Engl J Med. 2003 Sep 11;349(11):1015-6 [12968083.001]
  • [Cites] BMC Clin Pharmacol. 2004 Feb 9;4:1 [15028124.001]
  • [Cites] Scand J Prim Health Care. 1998 Sep;16(3):183-7 [9800233.001]
  • [Cites] J Adv Nurs. 1994 Jan;19(1):180-6 [8138622.001]
  • [Cites] Can J Nurs Adm. 1994 Sep-Oct;7(3):29-42 [7880844.001]
  • [Cites] Can J Nurs Adm. 1994 Nov-Dec;7(4):7-20 [7888410.001]
  • [Cites] Pharmacoeconomics. 1997 Aug;12(2 Pt 1):121-9 [10169665.001]
  • [Cites] Neurology. 1998 Sep;51(3):674-81 [9748009.001]
  • [Cites] Chest. 2004 Sep;126(3 Suppl):338S-400S [15383478.001]
  • (PMID = 17096858.001).
  • [ISSN] 1471-2296
  • [Journal-full-title] BMC family practice
  • [ISO-abbreviation] BMC Fam Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 5Q7ZVV76EI / Warfarin
  • [Other-IDs] NLM/ PMC1654161
  •  go-up   go-down


9. González Sánchez JL, Flores Murrieta G, Chávez Brambila J, Deolarte Manzano JM, Andrade Manzano AF: [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms]. Ginecol Obstet Mex; 2002 May;70:244-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms].
  • [Transliterated title] 5-fluorouracilo tópico en el tratamiento de la neoplasia intraepitelial vaginal.
  • OBJECTIVE: Our purpose was to determine the effectiveness of 5-fluorouracil (5-FU) in the treatment of vaginal intraepithelial neoplasia (VAIN).
  • MATERIALS AND METHODS: The study was performed in 30 patients with a mean age of 54 years and previous diagnoses from reviewed records and histopathology slides selected from a group of 65 patients with VAIN from 1980 to 1998.
  • Patients received intravaginal treatment with 5-FU, 1.5 g once weekly for 10 weeks and all patients were followed up for at least 2-years.
  • RESULTS: Twenty eight (93%) patients with VAIN had prior or concurrent anogenital squamous neoplasia, including 5 with invasive cervical carcinoma and 23 with cervical intraepithelial neoplasia.
  • In 23 of 30 treated patients (77%), VAIN went into remission after a single treatment; in 3, (10%), it went into remission after two treatment; 3 (10%) had recurrent VAIN 3; and in 1 (3%) it progressed to invasive vaginal cancer.
  • The treatment was well tolerated.
  • CONCLUSIONS: The 5-FU is an option choice for VAIN treatment.
  • Its use should be confined to treating extensive or multifocal high-grade VAIN.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Fluorouracil / therapeutic use. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Papanicolaou Test. Papilloma / drug therapy. Papilloma / pathology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12148464.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Fehr MK, Hornung R, Degen A, Schwarz VA, Fink D, Haller U, Wyss P: Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Lasers Surg Med; 2002;30(4):273-9
MedlinePlus Health Information. consumer health - Vulvar Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid.
  • BACKGROUND AND OBJECTIVES: To determine the feasibility of photodynamic therapy (PDT) of vulvar and vaginal condyloma and intraepithelial neoplasia (VIN, VAIN) and to compare PDT results with conventional treatments.
  • STUDY DESIGN/MATERIALS AND METHODS: Thirty-eight patients with vulvar or vaginal intraepithelial neoplasia (VIN) grade II/III (n = 22) or condyloma (n = 16) had 10% 5-aminolevulinic acid (ALA)-gel applied topically.
  • PDT was compared to conventional treatments for condyloma (CO(2) laser evaporation) and for VIN III (laser evaporation, surgical excision).
  • Of the neoplasia patients, none with hyperkeratotic VIN (n = 4) responded, and only one of four with increased pigmentation cleared.
  • Reduced disease-free survival (DFS) was associated with multifocal VIN (P = 0.02, OR 2.17, 95% CI 1.15-4.08), but DFS did not vary with treatment mode.
  • CONCLUSIONS: Although PDT is not equally efficacious for all subgroups, PDT for condyloma and intraepithelial neoplasia appears to be as effective as conventional treatments, but with shorter healing time and excellent cosmetic results.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Condylomata Acuminata / drug therapy. Photochemotherapy. Photosensitizing Agents / administration & dosage. Precancerous Conditions / drug therapy. Vaginal Diseases / drug therapy. Vaginal Neoplasms / drug therapy. Vulvar Diseases / drug therapy. Vulvar Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Female. Humans. Laser Therapy. Middle Aged

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Diseases.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11948597.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


11. Rémy V, Mathevet P, Vainchtock A: Vulvar and vaginal cancers and dysplasia in France--an analysis of the hospital medical information system (PMSI) database. Eur J Obstet Gynecol Reprod Biol; 2009 Dec;147(2):210-4
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vulvar and vaginal cancers and dysplasia in France--an analysis of the hospital medical information system (PMSI) database.
  • OBJECTIVE: Literature on the epidemiology of vulvar and vaginal cancers is scarce.
  • It has been reported that about 40% of vulvar and 70% of vaginal cancers may be linked to human papillomavirus (HPV).
  • This study aimed to assess the medical burden associated with hospitalizations and management of vulvar and vaginal cancers and dysplasia (VIN and VaIN) in France.
  • STUDY DESIGN: A retrospective analysis using the French national hospital database (PMSI) was performed to assess the annual number of patients hospitalized for vulvar and vaginal cancers and VIN/VaIN, based on hospital admissions in 2006.
  • Data for all stays and chemotherapy/radiotherapy sessions were extracted.
  • SAE database (Statistiques annuelles des établissements de santé) was used to take into account patients who had radiotherapy sessions performed in the private sector which are not reported in the PMSI.
  • RESULTS: In 2006, 1237 and 623 patients were hospitalized for vulvar cancer and VIN, respectively.
  • There were also 728 and 244 patients hospitalized for vaginal cancer and VaIN, respectively.
  • For all lesions except vaginal cancer, surgery was the most common type of management.
  • For vaginal cancer, medical care was the most prevalent (52%), followed by surgery (31%).
  • CONCLUSION: The burden of hospitalizations due to vulvar and vaginal cancers is substantial.
  • Further research is needed to assess the outpatient burden due to these diseases especially for precancerous dysplasia which may be mostly managed in an outpatient setting.
  • [MeSH-major] Hospital Information Systems. Vagina / pathology. Vaginal Neoplasms / epidemiology. Vulva / pathology. Vulvar Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19735968.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


12. Lilic V, Lilic G, Filipovic S, Visnjic M, Zivadinovic R: Primary carcinoma of the vagina. J BUON; 2010 Apr-Jun;15(2):241-7
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoma of the vagina.
  • In this paper we reviewed the risk factors for primary carcinoma of the vagina (PCV), diagnostic and therapeutic modalities, and principles leading to rational decision-making in the individualized management of vaginal carcinoma patients.
  • The leading risk factor for vaginal intraepithelial neoplasia (VAIN) and subsequent squamous cell vaginal carcinoma is long-lasting infection with human papillomavirus (HPV) type 16.
  • Prognosis of the disease depends on several factors, the most important of which are age, histologic type, and tumor stage.
  • Five -year survival rates are about 95% for stage 0, 75% for stage I, 60% for stage II, 35% for stage III, 20% for stage IVa, and 0% for IVb stage.
  • Due to its being a rare entity, there are still controversies as to the most optimal treatment.
  • Individualized treatment approaches have been increasingly used.
  • In most centres, standard treatment for this cancer is radiotherapy.
  • Some reports have shown that surgery might also be an option, while in some centres radiation is supplemented by cisplatin-based chemotherapy.
  • The supposed advantage of radiotherapy is the preservation of the anatomy and function of the vagina.
  • We believe that there are certain psychologic benefits with the preservation of the vagina, regardless of its function.
  • However, preservation of the vaginal function after treatment of invasive vaginal cancer is a rare phenomenon, both in the literature and from our own experience.
  • [MeSH-major] Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / epidemiology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Incidence. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplasms, Squamous Cell / pathology. Neoplasms, Squamous Cell / surgery. Prognosis. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20658716.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 45
  •  go-up   go-down


13. Li H, Geng L, Guo YL, Guo HY, You K, Qiao J: [Analysis of diagnosis and treatment of vaginal intraepithelial neoplasia and correlation to cervical intraepithelial neoplasia]. Zhonghua Fu Chan Ke Za Zhi; 2009 Mar;44(3):171-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of diagnosis and treatment of vaginal intraepithelial neoplasia and correlation to cervical intraepithelial neoplasia].
  • OBJECTIVE: To investigate the diagnosis and therapy of vaginal intraepithelial neoplasia (VAIN) and correlation to cervical intraepithelial neoplasia (CIN).
  • METHODS: The clinical and pathological data about age, liquid-based cytology, human papillomavirus (HPV) DNA test, colposcopy, histology types and treatment in 35 patients with VAIN were reviewed to investigate the diagnosis and therapy of VAIN and correlation to CIN.
  • 8% (1/13) of patients were younger than 40 years developed VAINIII, while 18% (4/22) patients were elder than 40 years.
  • There were 97% (33/34) cases with abnormality for liquid-based cytology and 86% (30/35) cases of lesions were located in the upper 1/3 vagina.
  • Among 19 cases received therapy, 14 cases (74%) were treated by surgery, 2 cases (11%) by brachytherapy, 3 cases (16%) used drug on the surface of vagina and the lesions were shown recovery in 9 cases followed up.
  • CONCLUSION: The clinical characteristics of VAIN are similar to CIN and the principles of diagnosis and treatment are also the same as that of CIN.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma in Situ / therapy. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / therapy. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Cervical Intraepithelial Neoplasia / therapy. Colposcopy. Cytodiagnosis / methods. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications. Papillomavirus Infections / diagnosis. Retrospective Studies. Treatment Outcome. Young Adult


14. Sun GH, Fu YT, Wu CJ, Chang SY: Povidone-iodine instillation for management of pelvic lymphocele after pelvic lymphadenectomy for staging prostate cancer. Arch Androl; 2003 Nov-Dec;49(6):463-6
Hazardous Substances Data Bank. Povidone-iodine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient who developed a symptomatic pelvic lymphocele after pelvic lymph node dissection for staging prostatic cancer was treated with percutaneous tube drainage, but the treatment was in vain.
  • Successful treatment was accomplished with povidone-iodine instillation into the lymphocele.
  • This simple, safe, and painless method for lymphocele treatment is recommended.
  • [MeSH-major] Anti-Infective Agents, Local / therapeutic use. Lymph Node Excision / adverse effects. Lymphocele / drug therapy. Postoperative Complications / therapy. Povidone-Iodine / therapeutic use. Prostatectomy. Prostatic Neoplasms / surgery
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography. Urinary Bladder / radiography. Urinary Bladder / ultrasonography

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14555330.001).
  • [ISSN] 0148-5016
  • [Journal-full-title] Archives of andrology
  • [ISO-abbreviation] Arch. Androl.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 25655-41-8 / Povidone-Iodine
  •  go-up   go-down


15. Iguchi M, Matsumoto M, Hojo K, Wada T, Matsuo Y, Arimura A, Abe K: Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma. Jpn J Clin Oncol; 2009 May;39(5):303-9
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Recombinant human interleukin-2 (rhIL-2) has been clinically used in the treatment of renal cell carcinoma (RCC).
  • METHODS: We established the subcutaneous tumor model by inoculating wild-type Renca cells into the backs of BALB/c mice, the pulmonary metastatic tumor model by an intravenous injection of luciferase-expressing Renca cells into the tail vain and the orthotopic tumor model by injecting luciferase-expressing Renca cells into the renal subcapsule.
  • These tumor-bearing mice were treated intra-peritoneally with rhIL-2 and/or per os with sorafenib.
  • CONCLUSIONS: The results suggest that the combination of rhIL-2 and sorafenib may offer significant potential as a novel therapeutic approach for patients with RCC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzenesulfonates / administration & dosage. Carcinoma, Renal Cell / drug therapy. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy. Pyridines / administration & dosage

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336449.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Interleukin-2; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Recombinant Proteins; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


16. Qi TS, Li GQ, Xu GJ: [Clinical observation on treatment of male infertility with positive antisperm antibody by self-formulated Xiaokang Zhongzi Recipe]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Nov;27(11):983-5
MedlinePlus Health Information. consumer health - Male Infertility.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation on treatment of male infertility with positive antisperm antibody by self-formulated Xiaokang Zhongzi Recipe].
  • OBJECTIVE: To observe the therapeutic effect of self-formulated Xiaokang Zhongzi Recipe (XZR) in treating male infertility with positive antisperm antibody (AsAb).
  • Clinical therapeutic effect and adverse reactions of the drugs were observed after 3 months of treatment.
  • RESULTS: In the trial group after treatment, 38 patients (69.1%) were cured, 14 (25.4%) improved and 3 treated in vain (5.5%, including 2 dropped out).
  • The negative conversion rate and average negative conversion time in the trial group and the control group were respectively 94.5%, (45 +/- 14) days and 41.8%, (62 +/- 21) days.
  • Significant difference between the two groups was shown in therapeutic effectiveness and average negative conversion time (P < 0.01).

  • Genetic Alliance. consumer health - infertility.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18173141.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Drugs, Chinese Herbal; 0 / xiaokang zhongzi
  •  go-up   go-down


17. Manna P, Sinha M, Sil PC: Protective role of arjunolic acid in response to streptozotocin-induced type-I diabetes via the mitochondrial dependent and independent pathways. Toxicology; 2009 Mar 4;257(1-2):53-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protective role of arjunolic acid in response to streptozotocin-induced type-I diabetes via the mitochondrial dependent and independent pathways.
  • Increasing evidences in both experimental and clinical studies suggest that oxidative stress is involved in the pathogenesis of diabetic tissue damage.
  • This study investigated the prophylactic role of arjunolic acid (AA) against STZ-induced diabetes in the pancreas tissue of the Swiss albino rats (as a working model).
  • We observed that STZ administration (at a dose of 65mg/kg body weight, injected in the tail vain) caused increased production of both ROS and RNS in the pancreas tissue of experimental animals.
  • Investigating the signaling pathways, we found that STZ administration caused the activation of phospho-ERK1/2, phospho-p38, NF-kappaB and destruction of mitochondrial transmembrane potential, release of cytochrome c as well as activation of caspase 3 in the pancreas tissue keeping the levels of total ERK1/2 and p38 significantly unchanged.
  • Treatment of animals with AA (at a dose of 20mg/kg body weight, orally) both prior and post to the STZ administration effectively reduced these adverse effects by inhibiting the excessive ROS and RNS formation as well as by down-regulating the activation of phospho-ERK1/2, phospho-p38, NF-kappaB and mitochondrial dependent signal transduction pathways leading to apoptotic cell death.
  • [MeSH-major] Antioxidants / pharmacology. Diabetes Mellitus, Experimental / drug therapy. Diabetes Mellitus, Type 1 / drug therapy. Hypoglycemic Agents / pharmacology. Mitochondria / drug effects. Pancreas / drug effects. Triterpenes / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blood Glucose / drug effects. Caspase 3 / metabolism. Cytochromes c / metabolism. Dose-Response Relationship, Drug. Lipid Peroxidation / drug effects. Male. Membrane Potential, Mitochondrial / drug effects. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. NF-kappa B / metabolism. Oxidative Stress / drug effects. Phosphorylation. Protein Carbonylation / drug effects. Rats. Reactive Nitrogen Species / metabolism. Reactive Oxygen Species / metabolism. Time Factors. Tumor Necrosis Factor-alpha / blood. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133311.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Blood Glucose; 0 / Hypoglycemic Agents; 0 / NF-kappa B; 0 / Reactive Nitrogen Species; 0 / Reactive Oxygen Species; 0 / Triterpenes; 0 / Tumor Necrosis Factor-alpha; 465-00-9 / arjunolic acid; 9007-43-6 / Cytochromes c; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


18. Wu YN, Jin Y, Pu LY: [Clinical observation on treatment of non-gonococcal cervicitis by integrative medicine]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Apr;25(4):362-4
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation on treatment of non-gonococcal cervicitis by integrative medicine].
  • OBJECTIVE: To explore the integrative medicinal therapy for non-gonococcal cervicitis (NGC) in order to elevate the therapeutic effect for patients treated in vain after long-term application of antibiotics.
  • CONCLUSIONS: The therapeutic effect of NGC treated by sensitive antibiotics combined with Qingyuan decoction is better than that treated with western medicine only.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892287.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


19. Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H: A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar;28(2):361-9
Hazardous Substances Data Bank. Chlorpromazine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second-generation antipsychotic medications have become popular as a treatment for schizophrenia.
  • Other psychotropic medications were simplified at the same time.
  • The number of antipsychotic medications and total psychotropic medications were significantly reduced from 3.5 to 1.1 and 6.8 to 2.6, respectively.
  • By showing successful cases, the authors suggest a possibility of antipsychotic monotherapy with a second-generation agent even for those patients who had been treated with high-dose antipsychotic polypharmacy in vain.
  • [MeSH-major] Antipsychotic Agents / therapeutic use. Polypharmacy. Schizophrenia / drug therapy
  • [MeSH-minor] Adult. Chlorpromazine / therapeutic use. Dose-Response Relationship, Drug. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Patient Readmission. Psychiatric Status Rating Scales. Pulse Therapy, Drug. Retrospective Studies. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14751434.001).
  • [ISSN] 0278-5846
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; U42B7VYA4P / Chlorpromazine
  •  go-up   go-down


20. Waldeck B: Beta-adrenoceptor agonists and asthma--100 years of development. Eur J Pharmacol; 2002 Jun 7;445(1-2):1-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The way to this position has been long and started with the first successful treatment of acute, severe asthma with s.c. injections of adrenaline 100 years ago.
  • Over the years, synthetic congeners of adrenaline have been produced and tested for their pharmacological properties.
  • Much effort was made to eliminate the next dose-limiting side effect, skeletal muscle tremor but in vain.
  • Throughout the 20th century, beta-adrenoceptor agonists have been developed and marketed as racemates.
  • The pharmacological activity usually resides in the (R)-enantiomer.
  • [MeSH-major] Adrenergic beta-Agonists / therapeutic use. Asthma / drug therapy. Receptors, Adrenergic, beta / physiology

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12065188.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Receptors, Adrenergic, beta
  • [Number-of-references] 150
  •  go-up   go-down


21. Hillegass WB: DES in saphenous bypass grafts: A treatment in vain? Catheter Cardiovasc Interv; 2008 Jul 1;72(1):21-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DES in saphenous bypass grafts: A treatment in vain?
  • [MeSH-major] Angioplasty, Balloon, Coronary. Drug-Eluting Stents. Graft Occlusion, Vascular / therapy. Myocardial Ischemia / therapy. Saphenous Vein / transplantation
  • [MeSH-minor] Humans. Immunosuppressive Agents / administration & dosage. Reoperation / adverse effects. Time Factors. Treatment Outcome. Tubulin Modulators / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Catheter Cardiovasc Interv. 2008 Jul 1;72(1):13-20 [18561143.001]
  • [CommentOn] Catheter Cardiovasc Interv. 2008 Jul 1;72(1):7-12 [18412239.001]
  • (PMID = 18561144.001).
  • [ISSN] 1522-726X
  • [Journal-full-title] Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • [ISO-abbreviation] Catheter Cardiovasc Interv
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Tubulin Modulators
  •  go-up   go-down






Advertisement